| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5521268 | Drug Discovery Today: Technologies | 2016 | 9 Pages |
Abstract
While immunomodulatory monoclonal antibodies (mAbs) have a wide therapeutic potential, exaggerated immunopharmacology may drive both acute and delayed immunotoxicity. The existing tools for immunotoxicity assessment do not accurately predict the full range of immunotoxicities observed in humans. New and optimized models, assays, endpoints and biomarkers in animals and humans are required to safeguard patients and allow them access to these often transformational therapies.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Frank R. Brennan, Andrea Kiessling,